The use of gene panel sequence for diagnostic and prognostic testing is now widespread, but there are so far few objective tests of methods to interpret these data. We describe the design and implementation of a gene panel sequencing data analysis pipeline (VarP) and its assessment in a CAGI4 community experiment. The method was applied to clinical gene panel sequencing data of 106 patients, with the goal of determining which of 14 disease classes each patient has and the corresponding causative variant(s). The disease class was correctly identified for 36 cases, including 10 where the original clinical pipeline did not find causative variants. For a further seven cases, we found strong evidence of an alternative disease to that tested. Many of the potentially causative variants are missense, with no previous association with disease, and these proved the hardest to correctly assign pathogenicity or otherwise. Post analysis showed that three-dimensional structure data could have helped for up to half of these cases. Over-reliance on HGMD annotation led to a number of incorrect disease assignments. We used a largely ad hoc method to assign probabilities of pathogenicity for each variant, and there is much work still to be done in this area.
INTRODUCTION
Genetic testing in clinical laboratories is becoming increasingly common: As of March 2017, GeneTests.org contains entries for about 706 laboratories and 1,083 clinics worldwide performing a total of 67,187 tests on 5,926 genes for 4,963 genetic conditions. So far though, there has been only limited testing of method efficacy (Cornish & Guda, 2015; Hwang et al., 2015; McCarthy et al., 2014; Pirooznia et al., 2014) .
Many of the genetic tests use targeted gene sequencing panels for identifying variants in a set of genes or gene regions that are known to be associated with a disease (Kammermeier et al., 2014; Okazaki et al., 2016) . In clinical laboratories specializing in specific diseases or classes of disease, panels provide high coverage data for genes of interest at relatively low cost, and also reduce the issues in reporting incidental findings to patients. A key and challenging step in all these tests is the ability to accurately interpret the genetic variants and assign a likelihood of pathogenicity (Richards et al., 2015) .
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Most clinical laboratories follow a semi-automated approach for variant interpretation, first making use of available variant annotation and prioritization tools and then checking the potential causative variants' association with the disease of interest in databases and the literature.
For the first step, there are dozens of annotation and prioritization tools (open-source or commercial) available (for example, Cingolani et al., 2012; McLaren et al., 2016; Robinson et al., 2014; Sifrim et al., Human Mutation. 2017; 38:1201 -1216 wileyonlinelibrary.com/journal/humu2013; Wang, Li, & Hakonarson, 2010) , typically providing potentially causative variants based on inheritance pattern, allele frequency (AF), genomic region of interest, mutation type, and in silico analysis of the likely impact of missense mutations. It has been demonstrated that there are substantial discrepancies between existing annotation tools (McCarthy et al., 2014; Pabinger et al., 2014) so that there is a clear need to encourage and monitor advances in this field. In most clinical laboratories, standard guidelines such as those from the American College of Medical Genetics and Genomics (ACMG) (Richards et al., 2015) are followed for variant interpretation and reporting. Although the guidelines accept computational predictions of pathogenicity for variants, these are only considered a "supportive" evidence. Other evidence is required to classify a variant as causative. As a consequence, the overall contribution of computational methods for variant classification is low and this motivates the development and testing of more accurate methods for variant interpretation.
Critical Assessment of Genome Interpretation (CAGI) is an orga- The data were made available to registered CAGI participants, and all were required to deposit disease and variant assignments by a specified deadline. The anonymized submissions were assessed by John-Marc Chandonia (http://enigma.lbl.gov/chandonia-john-marc/) and Shamil R. Sunyaev (http://genetics.bwh.harvard.edu/wiki/sunyae vlab/), and results were later discussed at the CAGI4 conference. A paper on the assessment is part of this CAGI special issue of Human Mutation (refer to Chandonia et al. CAGI issue paper when available). 
Building the gene list for disease classes
All the genes annotated in the two capture bed files (v01 and v02)
were extracted to compile a list of genes to examine. Lung Disease  ABCA3, AP3B1, CSF2RA, CSF2RB, *DKC1, FOXF1, HPS1, HPS4, NKX2-1,  SFTPA2, SFTPB, SFTPC, SLC7A7, *TERC, *TERT, *TINF2   Primary Ciliary Dyskinesia  CCDC103, CCDC39, CCDC40, DNAAF1, DNAAF2, DNAAF3, HEATR2,  DNAH11, DNAH5, DNAI1, DNAI2, DNAL1, HYDIN, LRRC6, were executed in a sequential manner (Fig. 1) . The inputs were the two VCF files and a gene configuration file that contained the genes associated with each disease class and their inheritance pattern (autosomal dominant/recessive, compound heterozygous, pseudoautosomal dominant/recessive, X-linked dominant/recessive).
Gene panel sequencing data analysis pipeline

Variant annotation
The two VCF files (one for SNVs and another for Indels) were anno- (Lek et al., 2016 ) and 1000 Genomes Phase-3 (Auton et al., 2015), mutation type (missense, nonsense, silent, frameshift, and non-frameshift indels), predicted impact on protein function, and previously associated phenotypes reported in ClinVar (Landrum et al., 2016) . Varant used dbNSFP (v2.9) (Jian, Boerwinkle, & Liu, 2014) database to fetch the mutation impact predictions from PolyPhen-2 (v2.2.2) (Adzhubei, Jordan, & Sunyaev, 2013) , SIFT (release January, 2015) (Kumar, Henikoff, & Ng, 2009 ) and CADD (v1.2) (Kircher et al., 2014) . The
RefGene (Pruitt et al., 2014) gene definition file was used for gene and transcript annotations. The principal isoforms of each gene were taken from the APPRIS database (Rodriguez et al., 2013) . In addition, the VCF files were annotated with SNPs3D (May, 2015) (Yue, Melamud, & Moult, 2006 ) mutation impact predictions, HGMD (version June 2014) (Stenson et al., 2003) disease-related variants and with dbscSNV (Jian et al., 2014) variants that potentially alter splicing. 
QC analysis
Identification of potentially causative variants
Only rare or novel variants rated high quality (marked PASS and with a GQ > 30 in the VCF files) were considered in the search for causal variants. At this stage, a rare variant was defined as one reported in ExAC (Lek et al., 2016 ) with a MAF less than or equal to 0.01 and a novel variant was defined as one not found in ExAC. Indels in low complexity regions (LCR) were excluded from the analysis, based on the LCR dataset computed for the human genome by Li (2014 or non-frameshift causing Indels, splice altering variants predicted in the dbscSNV database, and missense mutations predicted as damaging by one or more of SNPs3D, SIFT, PolyPhen-2, and CADD.
Category 3: Variants annotated as missense but not predicted to be damaging by any of the above methods, and UTR and intronic variants.
Category 4: All other variants (including synonymous and all with MAF > 0.1). These were not considered as potentially causative. Each variant was also grouped by frequency based on its ExAC MAF: group 1, novel; 2, very rare (MAF <= 0.005); or 3, rare (0.005 < MAF <= 0.01).
For each sample, the variant assigned to the lowest category was taken as the potentially causative variant. If there were two or more variants with the same category, the one in the lowest frequency group was selected. When there were two or more variants with the same category and frequency group, all were selected. Once a selection had been made, no other variants in that sample were considered. Category 1 variants were assumed to be of highest confidence, followed by category 2 and 3 variants and so selection was made in that order: If a suitable variant or variants were found in category 1, no category 2 ones were considered, and similarly, if suitable variants were found in category 2, no category 3 ones were considered. No phase information was available for these data, so for non-homozygous variants where the inheritance model of the gene containing the selected variant required a second allele as part of a compound heterozygous pair, the next ranked variant in that gene was selected.
Thus, for each of the 106 samples, the output from the module was usually one (for dominant or homozygous recessive situations) or two (for compound heterozygous situations) potentially causative variants in a particular gene. Since each gene is associated with one or more of the 14 disease classes (shown in Table 1 ), identification of a gene implied one or in some cases two possible disease classes.
For some samples, no potentially causative variants were found, or for compound heterozygous situations, only a single variant met selection criteria, and so no disease was identified. Table 2 lists the probability of pathogenicity assigned for each category of potentially causative variant. Category 1 variants (based on HGMD or ClinVar entries) were assigned a probability of 1.0, except for some missense variants where prediction methods suggested low impact.
Estimating probability for the disease
Category 2 missense variants were assigned a probability based on the extent of consensus among the four missense impact analysis methods used (SNPs3D, SIFT, PolyPhen-2, and CADD), utilizing a calibration from HGMD data and a control set of inter-species variants. That calibration shows a strong and approximately linear dependence of pathogenic probability on agreement between methods (Supp. Fig. S1 ).
Other variant types were subjectively assigned probabilities as shown in Table 2 . For autosomal recessive situations, the combined probability of pathogenicity was taken as the product of probabilities for the two contributing variants. Those values were incremented by 0.2 for homozygous cases, as an ad hoc correction for increased confidence, and by 0.1 in compound heterozygous situations. Based on this scoring scheme, a probability of pathogenicity for a disease class was generated for all the samples in which one or more potentially All other variants 0 causative variants were identified. For the cases in which a gene was associated with more than one disease class, equal probability was assigned for all the disease classes.
Post-challenge analysis
We performed many post challenge analyses on the results in order to gain insight into the performance, strengths, and weaknesses of the method, and in doing so, made a number of observations. We assessed performance based on the official answer key provided by the Johns Hopkins DNA Diagnostic Laboratory group. For each patient, the key specified the disease class, the possibly causative variants (if any) found in the subset of the 83 genes examined, and a classification of each of these variants (pathogenic, likely pathogenic, VUS (variant of uncertain significance), likely benign, and benign). The Hopkins classifications were based on the ACMG evidence rules (Richards et al. 2015) .
RESULTS
QC analysis summary
Supp. Figures S2 and S3 and Supp. Table S1 together with accompanying text provide details of the QC analysis. Overall, transition/transversion ratios and heterozygosity/homozygosity ratios are consistent with those found in 1000genome data, with the exception of one sample (P8) with excess homozygosity. There are a maximum of 2,000 low quality and 940 no-call calls per sample in the v01 capture data and lower numbers in v02. We expect that any causative variants at these positions would be missed. 
Missense mutations are amplified in the potentially causative variant set
The VCF files provided for the challenge have a total 2,311 unique variants across the 106 patients. This variant set consists of 40% intronic variants, 26% missense variants, 20% synonymous variants, and 14% of variants that are assigned as LoF (frameshift Indels, non-frameshift Indels, and nonsense), UTR, or splicing ( Fig. 2A) . After applying the PASS (PASS in VCF file), genotype (GQ > 30) and frequency filters (MAF <= 1% in ExAC), the total number of variants was reduced by almost 50% to 1,291, with 233 variants filtered because of low quality and 787 further variants filtered because of high MAF. Figure 2B shows that the frameshift and non-frameshift indels decreased the most (by 40% and 27%) on applying the PASS filter and NonSyn, Syn, UTR, CodingIntronic, and "Close to splice site" variants decreased the most (by 37%-42%) on applying the frequency filter. After all filtering, 138 out of the 1,291 variants were assigned as potentially causative by the prioritization procedure. In this set, the fraction of LoF variant is 16% and the fraction of missense variants is doubled to more than half (56%), while intronic variants drop to 8% and synonymous to 1%. The high fraction of potentially causative missense variants emphasizes the importance of correctly interpreting this class of mutation.
Matching individuals to disease class
Application of the categorization procedure described in Materials and Methods resulted in a non-zero probability for a specific disease The outer circle shows the distribution for all variants present in the VCF files provided as part of the challenge. The middle circle shows the distribution of high-quality rare variants after applying PASS, GQ, and frequency filters using data in the VCF file. The inner circle shows the distribution of potentially causative high quality rare and novel variants in 104 patients after applying the variant selection algorithm. Missense and loss of function variants are substantially enhanced in the latter set. (B) Changes in the variant type distribution during the filtering process, from total VCF variants, to those annotated as PASS, to those with low frequency, and finally those selected as potentially causative. The heat map indicates the percent decrease in variants on applying each filter (in the direction indicated by the arrows): The larger the decrease, the more orange; the smaller the decrease, the more green. The frameshift and non-frameshift Indel count decreased the most (by 40% and 27%) on applying the PASS filter and NonSyn, Syn, UTR, CodingIntronic, Close to splice site variants decreased the most (by 37%-42%) on applying the frequency filter class being assigned to 87 of the 106 patients. A further 17 patients were assigned a non-zero probability for two disease classes, as a consequence of a single gene being associated with two of the 14 disease classes. Two patients (P59 and P86) were not assigned to any disease class. P59 had the lowest average read depth for 50 genes out of 83 and next to lowest for the other 33 genes compared with other samples, suggesting that causative variants may have been missed.
Correct disease assignments also made by Hopkins
Overall, the assessors determined that we made correct disease assignments for 36 of 106 cases (Fig. 3A) , in the sense that the highest probability was assigned to the disease class specified in the Hopkins answer key. The Hopkins group reported "pathogenic," "likely pathogenic," or "VUS", based on ACMG variant classification, for 43 cases (Fig. 3B) . The VarP pipeline assigned the maximum probability to the same disease class for 26 of these 43 cases, with the same variants assigned as causative. There are two primary reasons for our non-identification of the other 17 cases (row 4 and row 8 in Fig.   3A ). First, for 10 of these patients, the Hopkins group found only one heterozygous variant in genes known to be associated with disease in a recessive inheritance pattern. Our method considered this insufficient evidence. Second, for the remaining seven patients, we found an alternative disease that ranked higher in the variant categorization scheme.
As noted in Materials and Methods, the selection scheme only considered the disease identified by the highest-ranked variants, and rejected all others. Had we considered diseases identified by lower confidence categorizations, five of these seven cases the Hopkins reported disease would have received 2nd ranking; one 3rd ranking; and one 4th ranking.
Additional correct disease assignments
Out of the 63 patients for which the Hopkins analysis found no causative variants in the genes ordered as part of the clinical test, our method made 10 correct assignments of disease class and assigned potentially causative variants (row 5 in Fig. 3A) . Seven of these patients were found to carry autosomal dominant or homozygous recessive variants and remaining three patients carried compound heterozygous variants. For nine of these 10 cases, the gene hosting the potentially causative variant was not analyzed by the Hopkins group, presumably because coverage was not selected by the requesting physician. For the remaining case, the Hopkins group did not report the potentially causative variant even though they analyzed the relevant gene. For the other 53 patients (row 6 and row 9 in Fig. 3A ), neither our method nor the Hopkins group found any causative variants for the expected disease class. However, we found potentially causative variants for a different disease in four of these patients, suggesting alternative diagnoses (see the Alternative Diagnosis section).
Assignment of probability
In order to estimate the accuracy of our probability model, we checked how well the probability of pathogenicity scores correlated with Distribution of patients with incorrectly assigned disease class versus estimated probability of pathogenicity. The dotted line shows the expected value in each bin (e.g., in the 0.8 to 1.0 bin, 10% of disease assignments are expected to be incorrect). Bars show the % of patients in each bin that actually have incorrect assignments. Bar colors show the number of patients with assignments made in each category (Category 1, most confidence). The error bar for each bin is the standard deviation of the number of patients in that bin. As should be the case for a good probability algorithm, patients with a high probability of a correct disease assignment do have a lower rate of incorrect disease classes. However, the plot also shows that there are 25 patients with high probability scores (> 0.8) but incorrect disease class. 15 of these patients carry variant(s) reported as pathogenic (tagged as DM) in the HGMD database. Reasons for this are discussed in the text incorrect disease class assignment. The dependence of incorrect disease assignment on assigned probability follows the correct trend, with a high fraction at low probability and a lower fraction at high probability (Fig. 4) . However, there are 25 patients with incorrect disease class assignments and a probability greater than 0.8. We found following reasons for this: (1) High confidence given to DM status HGMD variants-11 out of the 25 anomalies are of this type.
These are discussed below in the Selection section and listed in Table   4 . (2) In five cases, there were pairs of Indels (frameshift or nonframeshift) close together (less than 10 bp apart; Supp. (Fang et al., 2014) .
(3) In two cases, there are two heterozygous variants predicted damaging by three methods in genes associated with recessive disease.
It is possible that these are on the same copy of the gene (no phasing information was available). (4) In the remaining seven cases, we found possible alternative diagnoses. These are discussed in detail below.
Variant assignment accuracy for each selection category
As described in Materials and Methods, we used a work flow to assign variants to one of three categories, ranked by likelihood of pathogenicity. Table 3 shows the percent of correct disease assignments for variants in each category. The highest fraction of cases (42%, 11 out of 26) agreeing with the Hopkins disease class were based on category 1 variants. The corresponding fractions for category 2 and category 3 variants are 38% and 23%, respectively. This trend is expected, since assignment confidence decreases with increasing category number.
As noted earlier, category 1 variants are those annotated in HGMD and/or ClinVar as disease-causing. Further inspection showed that 11 out of the 15 discordant assignments cases had conflicting database annotations and sometimes weak or no supporting evidence (Table   4 ). In seven cases, the corresponding variant is annotated "DM" (disease mutation) in HGMD but is annotated "benign" or "likely benign" in As discussed later, these four patients may really have a different disease.
TA B L E 3 Percentage of correct disease assignments in each of the three variant selection categories
Category 2 variants are those selected because of being a LoF variant, the computational method assigning pathogenicity for missense variants, a direct hit on a splice site, or a prediction of an impact on splicing (Jian et al., 2014 Category 3 variants are missense mutations predicted benign by all four computational methods and those which are intronic or in a UTR.
All were assigned low causative probability, ranging from 0.05 to 0.29.
There are only seven out of 30 with correct disease class assignments that were assigned based on category 3 potentially causative variants.
Six of these seven cases carried intronic insertions or deletions close to a splice site (within 5-30 bases), suggesting proper treatment of this mechanism is important. The remaining case carries a missense mutation predicted benign by the four mutation impact prediction methods.
There is a marked dependence of level of agreement with the Hopkins disease class and the frequency of the potentially causative variants (Table 3) : 49% of disease assignments made for novel variants agree with the Hopkins answer key, compared with 27%-30% for the other, non-novel variants with less than 1% MAF.
Alternative diagnoses
There is an important difference between the Hopkins laboratory procedures and the CAGI challenge. In the laboratory, in accordance with clinical guidelines, for each patient, variant analysis was performed only on the subset of genes identified by the physician requesting the test, usually those for a single disease, and sometimes only a subset of genes for a single disease. On the other hand, the challenge required analysis of all genes for each patient. That led to a number of findings suggesting that in some cases, causative variants are overlooked in the clinic. Of the 70 cases where our disease assignments and the disease tested by the Hopkins pipeline differ, seven have strong evidence supporting assignment to a different disease (Table   5 ). In four of these cases, no variants supportive of the tested disease were found by ourselves or by Hopkins. In two further cases, the Hopkins pipeline reported only one variant in a recessive gene and for the remaining case (patient P8 in Table 5 ), there is evidence that the patient may have two diseases. These seven cases fall into three groups: Note: MAF, minor allele frequency. These variants were present in 11 patients. splicing (Pagani et al., 2003) . This patient was originally tested for Peroxisomal Beta-Oxidation Defects and a homozygous recessive frameshift mutation was found in the relevant gene. We did not report that variant because of finding the CFTR variant which we categorize as higher confidence of pathogenicity. The data are consistent with the patient having both diseases.
TA B L E 5
Three cases where the patient carried variant(s) predicted dam-
aging by all reporting computational methods or a LoF variant.
For example, one of these is a patient (P46) to whom we assigned 
Protein structure coverage for potentially causative variants
In principle, information from three-dimensional structure and on the detailed functional roles of residues, motifs, and domains should be of considerable value in evaluating the impact of missense variants.
In practice, it is often ignored, and indeed we did not use it in this challenge. What difference might it have made? To investigate this, we considered only potentially causative missense variants that are not included in HGMD or ClinVar. Current ACMG guidelines (Richards et al., 2015) would place a low weight on computational analysis of these, and thus they would likely be reported as VUSs. There are 47 such missense variants distributed over 41 patients. ∼50% (23/47) of these are either included in an experimental structure or can be included in a homology model based on 22% or higher sequence identity to an experimental structure (Fig. 5A) . Three of these mutations are in proteins with experimental structure (X-ray structure). We use these three cases to illustrate how protein structure could be used to: (Hol, Halie, & Sander, 1981) , consistent with significant destabilization of the structure (Fig. 5C ). Loss of protein stability has been shown to be the most common cause of monogenic disease (Wang & Moult, 2001; Yue, Li, & Moult, 2005) . A different mutation at this position (rs77902683, NM_000492.3:c.3848G>T, p.(R1283M)) has previously been found in CF patients (Cheadle, Meredith, & al-Jader, 1992 ) and has been reported as pathogenic in ClinVar and HGMD.
The third mutation with experimental structure coverage is one where we made an incorrect disease assignment on the basis of just one of the four missense analysis methods predicting deleterious.
Although that was already a low confidence prediction, further evidence would be useful. This is a very rare ( 
DISCUSSION
Undiagnosed cases
Even with full knowledge of the reported disease class, the Hopkins pipeline could only find potential causative variants for 43 cases, leaving 63 with no causative variants. As discussed below, we were able to find variants correctly matching a further 10, but that still leaves half (53) and larger scale structural genomic changes. In some rare disease analyses using whole genome sequence, such as in the SickKids Genome Clinic (http://www.sickkids.ca/CGM/genome-clinic/index.html), the latter type of variant has been found to make a significant contribution (Stavropoulos et al., 2016) . However, those patients mostly exhibit major developmental disease phenotypes, and may not be typical of rare disease patients in general.
Correct diagnosis for cases where the Hopkins pipeline did not find causative variants
For 10 cases, we were able to identify the reported disease class even though Hopkins reported no potentially causative variants. In nine out of these 10 cases, the Hopkins pipeline did not include analysis of the gene carrying the diagnostic variant(s 
Missed diagnoses
There are 17 cases where we did not identify the correct disease class, but the Hopkins analysis did find potentially causative variants. and ignoring all other variants in a patient was sub-optimal. A better procedure would probably be to use all variants in each gene to assign a probability of pathogenicity and to use those probabilities to infer disease class.
Incorrect diagnoses
For 25 patients VarP made high confidence (probability score > 0.8) incorrect disease class assignments. A primary factor was again overreliance on HGMD annotation, accounting of 11 out of the 25 cases.
A further five cases involved pairs of Indels very close to each other (less than 10 base pairs apart), and consistent with a compound heterozygous cause for a recessive disease. In fact, these Indel pairs are probably coupled alignment errors. There are two cases where the assumption that a pair of recessive variants are on different copies of the gene may be incorrect (there was no phasing data available). In seven of the remaining cases, we found high confidence pathogenic variants in genes associated with a different disease from that in the Hopkins answer key. As discussed later, the evidence for some of these is sufficiently strong that they may not be errors.
Distinct potentially causative variants that led to disease classification
VarP identified 105 potentially causative variants each of which occurs once in a total of 78 patients. A further 14 potentially causative variants were seen in two or more of the other 28 patients (Supp . Table S3 ).
We also considered accuracy in terms of the fraction of these 119 distinct variants which led to correct and incorrect disease assignments.
By this measure, correct disease identification increases from 34% (36 out of 106) to 36% (33 out of 91). The improvement occurs because the majority of repeat variants are present in cases where an incorrect disease was assigned, and we speculate that some of these may reflect sequencing artifacts.
Reliability of probability for disease assignments
In the clinic, perhaps more important than having an accurate method of determining pathogenicity is having an accurate method for assigning a probability of correctness to a pathogenic assignment. The CAGI challenge required participants to also provide these probabilities, and so it was possible to evaluate how effective our approach was. We used a largely ad hoc probability scale in this analysis. Although there is a reasonable overall correlation between these quantities (Fig. 4) , there were a substantial number of variants assigned a high probability that were not in fact pathogenic. There were two primary reasons for thatfirst, as noted earlier, we misjudged the reliability of HGMD assignments of disease mutations. Had we used a model that included disagreements between HGMD and ClinVar, these cases would have had more appropriate probabilities. Second, as discussed below, in a number of cases we consider the evidence strong that these patients had a different disease.
Reliability of missense probability estimates
As described in Results, overall, the estimated probabilities of pathogenicity shows qualitative though not quantitatively correct properties. The majority of potentially causative variants are missense, so improved confidence in assigning a probability of pathogenicity to these are of particular importance. As described earlier, we assigned a probability based on the fraction of four different missense analysis methods reporting deleterious. The method was calibrated (Yin et al.)
using a set of HGMD mutations (all assumed pathogenic) and a set of interspecies variants (assumed benign). There are a number of limitations to this dataset, and so we were interested to see to what extent the estimated probabilities were useful. Interpretation of the results is complicated by the alternative diagnosis cases and by compound heterozygous cases, involving two different variants. Supp. Figure S5 shows the relationship between estimated probabilities and correct disease class assignment, omitting those cases. Counts here are too small to draw firm conclusions. A high proportion of mutations assigned with a probability of less than or equal to 0.5 are incorrect, consistent with expectations. However, more than half of the mutations with probabilities higher than 0.7 are also incorrect, 
Apparent cases of alternative diagnoses
Using quite stringent criteria we identified seven cases where the data are consistent with patients having a different disease class than that provided in the Hopkins answer key. Four of these patients carry variants for the alternative disease class that are reported in HGMD and ClinVar as pathogenic. The remaining cases carry missense variants predicted damaging by all reporting methods, frameshift or nonframeshift indels, or variants directly affecting splicing. In three cases, symptoms of the answer key disease and the alternative overlap, so it is possible that there was a misdiagnosis in the referring clinic. The other cases are more puzzling. Since we have no information as to why a particular test was ordered (and in many cases the Hopkins group may not either), it is difficult to comment further. But it is concerning that in a number of cases there could be confusion of some sort as to what disease patients have. In these seven cases, the Hopkins pipeline did not report any variant for four cases, reported only one variant in a recessive gene for two cases and reported a homozygous frameshift mutation in the remaining case. The pipeline was prevented from discovering the possible alternatives by the current guidelines, which require that only requested genes for a specific disease test be examined. On the basis of these limited data, it is not clear whether on balance this practice is in the patients' best interest. As discussed earlier, these patients each carry only one heterozygous variant in a recessive gene, which we considered insufficient evidence.
VarP performance improves when the patients' clinical indications are known
Better results would have been obtained not using HGMD
As noted earlier, 11 of the 25 incorrect disease class assignment cases with a probability of pathogenicity higher than 0.8 are a result of accepting HGMD annotations of pathogenicity. Such a high error rate from a single cause suggests that it might be better to ignore HGMD altogether and just use ClinVar for pathogenicity information. We tested this by running the VarP pipeline again, omitting HGMD. The success rate (correct match to disease class) increases from 36 to 40 (Supp . Table S4 ).
Lessons learned
Going forward, how would we now improve performance of the VarP analysis pipeline? As noted earlier, a suboptimal feature of the procedure was terminating the variant search once a suitable candidate had been found, rather than finding all possible causative variants and assigning each a probability. As also noted earlier, over-reliance on HGMD was a cause of errors and this can be corrected by considering ClinVar and HGMD annotations together, and, where appropriate, include missense impact analysis in assigning a probability to these category 1 variants. Structure also has the potential for contributing to the discovery of causative variants and providing mechanistic insight.
However, full automation of that analysis will require the development of new methods. In general, much more work must be done to provide a reliable probability of pathogenicity, not only for missense but for all types of variants.
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